Research

The Defend 1050 was shown to reduce 99.99% of aerolized Enterobacter cloacae, Salmonella enterica and Listeria innocua in 15 minutes and exceeded a 6 net log reduction in 20 minutes.

Novaerus caused severe damage to cell structure of aerosolized Escherichia coli (E. coli).

Novaerus Defend 1050 was shown to reduce 99.9% of airborne Influenza A within the first 10-20 minutes of operation.

Novaerus Defend 1050 was shown to reduce aerosolized Aspergillus niger spores.

Novaerus Protect 800/900 was shown to reduce 99.99% of methicillin-resistant Staphylococcus aureus (MRSA) within 4 hours.

Novaerus Defend 1050 achieved 55-89% DEHS particle reduction and 90% toluene removal after 6 -17 minutes, dependent on fan speed.

Novaerus Protect 800/900 was shown to reduce aerolized biologicals: Staphylococcus epidermidis (99.87% reduction), MS2 bacteriophage (99.99% reduction), Aspergillus niger fungus (98.85% reduction), and Bacillus subtilis endospores (86.5% reduction).

Novaerus shown to reduce overall allergens by 41.16%, including house dust mites, feline dander, canine dander, and pollen.

Novaerus Protect 800/900 was shown to reduce formaldehyde by 85% during a 14-hour testing experiment.

The Novaerus Protect 200 rendered all airborne Mycobacterium tuberculosis non-viable.

Novaerus shown to reduce 95% of Staphylococcus epidermidis aerosol contamination in 30 minutes.

Novaerus caused severe size and shape change to cell structure of aerosolized Staphylococcus epidermidis and Aspergillus niger.

Novaerus Protect 200 passed standard UL testing with a maximum ozone concentration of 0.037 ppm.

Novaerus Protect 800 passed standard UL testing with a maximum ozone concentration of 0.017 ppm with fan on high speed setting and 0.020 ppm with fan on low speed setting.

Novaerus reduces VOCs by 93%, airborne bacteria by 87% and moulds by 67%.

Novaerus shown to reduce airborne Staphylococcus by 100%, airborne bacteria by 89% and airborne fungi by 87%.

Novaerus reduces staff sickness, ward odours, infections and antibiotic use. Wards with Novaerus have had no outbreaks of MRSA, C. diff, influenza, or norovirus since installation.

Novaerus reduces environmental surface MRSA by 97% and reduces environmental surface TVC and environmental air MRSA.

Novaerus shown to reduce airborne bacteria and fungi 96%.

Novaerus plasma technology shown to significantly reduce number of microorganisms.

Novaerus shown to reduce bacterial loads on high surfaces and window sills as well as reduce overall infection rates by 23% compared to increase of infection rates by 35% in control section.

Novaerus devices effectively reduce the number of airborne pathogens by 61% in the admission room of the Paediatric Department and by 19% in the Clinic of Pulmonology/Tuberculosis and Pulmonary Diseases.

Novaerus reduces CFU rates by 82% and fungi count by 93% after 2 months of operation.

Novaerus devices significantly reduce number of microorganisms as well as eliminate unwanted odours.

This 35-month study compares the total number of respiratory nosocomial infections and infection rates before and after each implementation of the Novaerus technology.

This 20-month study compares the total number of respiratory nosocomial infections before and after implementation of the Novaerus technology.

Since 2014, the Haus an der Traisen nursing home in St. Pölten have supplemented their existing hygiene protocols with Novaerus air purification units to help control infection and reduce odour.

This 24-month study compares the total number of repeat infections, nosocomial C. difficile infections, and nosocomial respiratory infections before and after implementation of the Novaerus technology.

Linde Healthcare, a Vienna-based healthcare company, had no existing healthy air solution in place for its 16 person open floorplan office space. Curious about Novaerus’s innovative technology, they reached out to learn more.

This 24-month study compares the total number of nosocomial respiratory infections and nosocomial C. difficile infections before and after implementation of the Novaerus technology.

This 24-month study compares the total number of nosocomial respiratory infections before and after implementation of the Novaerus technology.

This 28-month study compares the total number of nosocomial respiratory infections and nosocomial C. difficile infections before and after implementation of the Novaerus technology.

This 29-month study compares the average monthly rate of nosocomial respiratory infections before and after implementation of the Novaerus technology.

Sante International has provided solutions to the Romanian healthcare industry since 1992 and has partnered with Novaerus since 2014. Over a 3-month period, they proved Novaerus technology is more efficient and safer with no maintenance and at a low cost.

As part of a trial to measure background pollution and pathogenic organisms, Novaerus units were placed in 4 locations in the University of Szeged’s Department of Geriatrics and Chronic Diseases of the Internal Medicine Clinic No. 1. The medical clinic was interested in improving overall air quality in the geriatric and chronic disease wards.

This 24-month study compares the total number of nosocomial respiratory infections before and after implementation of the Novaerus technology.

This 23-month study compares the total number of nosocomial respiratory infections before and after implementation of the Novaerus technology.